

PATENT
Docket No. 529492000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mark A. SCHENA

Serial No.: 09/613,006

Filing Date: July 10, 2000

For: MICROARRAY METHOD OF
GENOTYPING MULTIPLE SAMPLES
AT MULTIPLE LOCI

Examiner: B. Forman

Group Art Unit: 1634

DECLARATION OF MARK A. SCHENA
PURSUANT TO 37 C.F.R. § 1.131

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

I, Mark A. Schena, declare as follows:

1. I am the sole inventor named in the above-referenced patent application, and I am familiar with the contents thereof.
2. The work was completed by me or under my direction.
3. I conceived of the invention claimed in the subject application prior to February 16, 2000.
4. I have worked diligently on reducing to practice the claimed invention in the subject application since before February 16, 2000 until the application was filed on July 10, 2000.

5. The following paragraph summarizes the document attached to this declaration which is submitted as evidence that I conceived of the claimed invention in the subject application prior to February 16, 2000. The attached document was prepared in the U.S. All of the activities reported in the document occurred in the U.S. With respect to this document, dates and portions that are not relevant to this declaration have been redacted.

6. Exhibit A is evidence of my conception of the claimed invention in the subject application. The conception was made on a date prior to February 16, 2000.

7. The following paragraph summarizes the documents attached to this declaration which are submitted as evidence that I was diligent in reducing the claimed invention in the subject application to practice. All of the attached documents were prepared in the U.S. prior to the filing date of July 10, 2000. All of the activities reported in these documents occurred in the U.S. in a diligent manner during a period commencing prior to February 16, 2000 and ending prior to July 10, 2000. With respect to all of these documents, dates (all of which are prior to July 10, 2000) and portions that are not relevant to this declaration have been redacted.


8. Exhibit B shows computer files and pages from my laboratory notebooks that show that I worked diligently on the reduction of the claimed invention to practice. Pages 1 – 6 show computer files of data generated from experiments. Page 7 shows the sequences of oligonucleotides used in experiments. Page 8 shows a protocol used in the experiments. Page 9 shows the sequences of oligonucleotides used in the experiments. Pages 10 – 11 show a sequence alignment generated in the experiments. Pages 12 – 14 show the sequences of oligonucleotides used in the experiments. Pages 15 – 18 show nucleotide sequences analyzed in the experiments. Pages 19 – 21 show protocols used in experiments. Page 22 shows numerical microarray data. Pages 23 – 30 show pictorial microarray data.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

5/3/03
Date

Mark A. Schena
Mark A. Schena

NOTES



∴ Multiple patients + multiple
diseases in one test ⇒ Cost-effective!

- Vizit board
- Aharan re: Stranberg MS?

Exhibit B




Exhibit B




Exhibit B




Exhibit B




Exhibit B




Exhibit B




Exhibit B

ARDC-110 (Green Label, Sickle Cell WT)
5' NGA CTC CTG (A/T)GG AGA A 3'
N = Cy3

A1 → E1
+
A3 → E3

ARDC-111 (Red Label, Sickle Cell C allele)
5' NGA CTC CTA (A/T)GG AGA A 3'
N = Cy5

ARDC-112 (Red Label, Sickle Cell WT)
5' NTG GTG GTG AGG CCC T 3'
N = Cy5

ARDC-113 (Green Label, Sickle Cell S allele)
5' NTG GTG GTA AGG CCC T 3'
N = Cy3

ARDC-114 (Green Label, CF WT)
5' NAT CAT CTT TGG TGT T 3'
N = Cy3

ARDC-115 (Red Label, CF ΔF508)
5' NTA TCA TCG GTG TTT C 3'
N = Cy5

ARDC-116 (Red Label, GALT Q188R WT)
5' NCA CTG CCA GGT AAG G 3'
N = Cy5

ARDC-117 (Green Label, GALT Q188R mutant)
5' NCA CTG CCG GGT AAG G 3'
N = Cy3

ARDC-118 (Green Label, N314D WT)
5' NCA ACT GGA ACC ATT G 3'
N = Cy3

ARDC-119 (Red Label, N314D mutant)
5' NCA ACT GGG ACC ATT G 3'
N = Cy5

b. Plasmid DNA can be prepared by alkaline lysis and purified. The 96-well REAL prep (Qiagen #SQ811 and #19504) facilitates rapid preparation.

[Back to Table of Contents](#)

Protocol 4. Microarray manufacture and processing.

Reagents and Equipment

- Micro-spotting robot (Various)
- Stealth Micro Spotting Device (TeleChem)
- SuperAldehyde Substrates (TeleChem)

Method

1. Obtain cilylated (active aldehyde) microscope slides (CEL Associates).
2. Print amino-linked cDNAs using a micro-spotting device according to the manufacturer's instructions.
3. Allow printed microarrays to dry overnight in a slide box^a.
4. Soak slides twice in 0.2% SDS for 2 min at room temperature with vigorous agitation^b.
5. Soak slides twice in ddH₂O for 2 min at room temperature with vigorous agitation.
6. Transfer slides into ddH₂O at 95-100°C for 2 min to allow DNA denaturation.
7. Allow slides to dry thoroughly at room temperature (~5 min).
8. Transfer slides into a sodium borohydride solution^c for 5 min at room temperature to reduce free aldehydes.
9. Rinse slides three times in 0.2% SDS for 1 min each at room temperature.
10. Rinse slides once in ddH₂O for 1 min at room temperature.
11. Submerge slides in ddH₂O at 95-100°C for 2 seconds^d.
12. Allow the slides to air dry and store in the dark at 25°C (stable for >1 year).
 - a. Drying increases crosslinking efficiency. Several days or more is acceptable.
 - b. This step removes salt and unbound DNA.
 - c. Dissolve 1.0 g NaBH₄ in 300 ml phosphate buffered saline (TDS). Add 100 ml 100% ethanol to reduce bubbling. Prepare JUST PRIOR to use!
 - d. Heating the slides greatly aids in the drying process.

Method

1. Prepare a 15-mer^a oligonucleotide microarray wherein the central (8th) position identifies the polymorphism or mutation in the fluorescent sample^b. Microarrays are made by spotting 10-100 pmole/μl oligonucleotides in 1X micro-spotting solution.
2. Process the microarray to remove unbound 15-mer.
3. Prepare a fluorescent sample by PCR amplification of the locus encompassing the polymorphism or mutation^c. Use ~1/10 of a 100 μl PCR reaction for hybridization of a sample that contains <1,000 loci. Purify the sample prior to hybridization by ethanol precipitation or spin column purification.
4. Denature the sample by boiling for 2 min prior to hybridization^d.
5. Hybridize the fluorescent sample to the oligonucleotide microarray for 4 hrs at 42°C^e.
6. Wash the microarray to remove unhybridized sample as follows: twice for 5 min each at room temperature in 2X SSC, once for 5 min at room temperature in 2X SSC.
7. Allow the microarray to air dry.
8. Scan the microarray at the highest PMT and laser settings that preserve linearity and minimize background^f.
9. Quantitate fluorescence intensities with ImageOne software.
- a. Oligonucleotides must be coupled covalently to the solid support. We have used microscope slides with reactive aldehyde groups and primary amines on the oligonucleotides to mediate covalent end attachment.
- b. The central or 8th position in a 15-mer is used to identify a single base polymorphism or mutation by hybridization. For a marker in which the wild type is a "G" and the mutant is a "T", the two complementary 15-mers would be identical except at position 8 in which the wild type 15-mer would contain a "C" and the mutant oligonucleotide would contain an "A".
- c. Fluorescent primers spanning the site of interest by ~60-bp will yield a product that hybridizes efficiently to the oligonucleotide microarray.
- d. Double-stranded fluorescent products must be denatured prior to hybridization. Single-stranded fluorescent samples made by Mosaic PCR are preferable.
- e. Hybridization temperature should be ~10°C below the T_m. 42°C works well for 15-mers. The temperature should be adjusted for longer or shorter oligonucleotides.
- f. On the ScanArray 3000, laser and PMT settings of 70% and 80%, respectively, work well for most genotyping applications.

[Back to Table of Contents](#)

Literature Cited

1. M. Schena and R.W. Davis (1998). Genes, Genomes and Chips. In DNA Microarrays: A Practical Approach (ed. M. Schena), Oxford University Press, Oxford, UK, in press.
2. Schena, M. and R.W. Davis (1998). Parallel Analysis with Biological Chips. In PCR Methods Manual (eds. M. Innis, D. Gelfand, J. Sninsky), Academic Press, San Diego, in press.
3. Lemieux, B., Abruzzo, A., and M. Schena (1998). Overview of DNA Chip Technology. Molecular Breeding 4, 277-280.
4. Schena, M., Heller, R.A., Thibault, T.P., Konrad, K., Lachametz, E., and R.W. Davis (1998). Microarrays: biotechnology's discovery platform for functional genomics. Trends in Biotechnology 16, 301-306.
5. Heller, R.A., Schena, M., Chai, A., Shalon, D., Bedilion, T., Gilmore, J., Woolley, D.E., and Davis, R.W. (1997). Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proceedings of the National Academy of Sciences USA 94, 2150-2155.
6. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P.O., and R.W. Davis. (1996). Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1,000 Genes. Proceedings of the National Academy of Sciences USA 93, 10614-10619.
7. Schena, M. (1996). Genome analysis with gene expression microarrays. BioEssays 18, 427-431.
8. Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470.

Exhibit B

EOS BIOTECHNOLOGY: OLIGO RECORD FILE

Run Title: ArrayIt
 340 Plate 1
 NOTES: "Cy3/Cy5/Aminolink 15mers, and Aminolink 20mers"

SERIAL NUMBER:		300003401							
#	NAME	5'SP	5' --> 3' SEQUENCE	Plate	Row	Plate Col.	Run	Comment	
	amount (ug)	amount (nmol)							
1	ARDC-110	CY3	GACTCCTGWGGAGAA	A	1	23.42	4.82	} Cy3 probe	
2	ARDC-113	CY3	TGGTGGTAAGGCCCT	B	1	32.92	6.77		
3	ARDC-114	CY3	ATCATCTTTGGTGTT	C	1	33.30	6.93		
4	ARDC-117	CY3	CACTGCCGGGTAAGC	D	1	29.24	6.02		
5	ARDC-118	CY3	CAACTGGAACCATTG	E	1	25.85	5.39		
6	ARDC-110	CY3	GACTCCTGWGGAGAA	F	1	24.54	5.05		
7	ARDC-113	CY3	TGGTGGTAAGGCCCT	G	1	29.27	6.02		
8	ARDC-114	CY3	ATCATCTTTGGTGTT	H	1	27.18	5.66		
9	ARDC-117	CY3	CACTGCCGGGTAAGG	A	2	26.59	5.48	} Cy5 probe	
10	ARDC-118	CY3	CAACTGGAACCATTG	B	2	25.93	5.40		
11	ARDC-110	CY3	GACTCCTGWGGAGAA	C	2	21.59	4.44		
12	ARDC-113	CY3	TGGTGGTAAGGCCCT	D	2	34.51	7.10		
13	ARDC-114	CY3	ATCATCTTTGGTGTT	E	2	36.17	7.53		
14	ARDC-117	CY3	CACTGCCGGGTAAGG	F	2	28.14	5.80		
15	ARDC-118	CY3	CAACTGGAACCATTG	G	2	27.07	5.64		
16			H 2						
17	ARDC-111	CY5	GACTCCTAWGGAGAA	A	3	26.60	5.49		
18	ARDC-112	CY5	TGGTGGTGAGGCCCT	B	3	32.80	6.72		
19	ARDC-115	CY5	TATCATCGGTGTTTC	C	3	20.76	4.34		
20	ARDC-116	CY5	CACTGCCAGGTAAGG	D	3	23.47	4.85		
21	ARDC-119	CY5	CAACTGGGACCATTG	E	3	22.62	4.70		
22	ARDC-111	CY5	GACTCCTAWGGAGAA	F	3	22.88	4.72		
23	ARDC-112	CY5	TGGTGGTGAGGCCCT	G	3	26.28	5.39		
24	ARDC-115	CY5	TATCATCGGTGTTTC	H	3	17.87	3.73		
25	ARDC-116	CY5	CACTGCCAGGTAAGG	A	4	22.40	4.63		
26	ARDC-119	CY5	CAACTGGGACCATTG	B	4	31.33	6.51		
27	ARDC-111	CY5	GACTCCTAWGGAGAA	C	4	24.06	4.97		
28	ARDC-112	CY5	TGGTGGTGAGGCCCT	D	4	36.45	7.47		
29	ARDC-115	CY5	TATCATCGGTGTTTC	E	4	23.95	5.00		
30	ARDC-116	CY5	CACTGCCAGGTAAGG	F	4	26.93	5.56		
31	ARDC-119	CY5	CAACTGGGACCATTG	G	4	31.42	6.52		
32			H 4						
33	ARDC-120	L	TTCTCCWCAGGAGTC	A	5	21.64	4.38	} Assume 5 wait us Control Oligos.	
34	ARDC-121	L	AGGGCCTCACCACCA	B	5	40.17	8.16		
35	ARDC-122	L	AACACCAAAGATGAT	C	5	30.43	6.09		
36	ARDC-123	L	CCTTACCTGGCAGTG	D	5	26.44	5.33		
37	ARDC-124	L	CAATGGTTCCAGTTG	E	5	28.09	5.62		
38	ARDC-120	L	TTCTCCWCAGGAGTC	F	5	20.54	4.16		
39	ARDC-121	L	AGGGCCTCACCACCA	G	5	21.05	4.28		
40	ARDC-122	L	AACACCAAAGATGAT	H	5	22.33	4.47		
41	ARDC-123	L	CCTTACCTGGCAGTG	A	6	27.25	5.49		
42	ARDC-124	L	CAATGGTTCCAGTTG	B	6	31.92	6.38		
43	ARDC-120	L	TTCTCCWCAGGAGTC	C	6	19.84	4.02		
44	ARDC-121	L	AGGGCCTCACCACCA	D	6	22.79	4.63		
45	ARDC-122	L	AACACCAAAGATGAT	E	6	30.10	6.03		
46	ARDC-123	L	CCTTACCTGGCAGTG	F	6	29.27	5.90		
47	ARDC-124	L	CAATGGTTCCAGTTG	G	6	25.90	5.18		

Exhibit B

[illegible]

~~001401317-1~~ Human Data visible only on discussion 11
length = 73108

Score = 2260 bits (1140), Expect = 0.0
Identities = 1140/1140 (100%)
Strand = Plus / Plus

```

Query: 1      cttaccagaaagcttcttaatccaaatcaggagagagatctgcttagaacttaggttagagttt 60
              |||
             61621 cttaccagaaagcttcttaatccaaatcaggagagagatctgcttagaacttaggttagagttt 61620

```

Query: 61 tcatccatctctctctgaagatcttctcatattctggagcgcaggagatccatct 120
 Shift: 61681 tcatccatctctctctgaagatcttctcatattctggagcgcaggagatccatct 61740

```
Query: 121   acatcccccaagctgaattatggttagacaaagtcttccacttttagtgcatcatttc 180  
            |||||  
Sbjc: 61741    acatatcccccaagctgaattatggttagacaaagtcttccacttttagtgcatcatttc 61800
```

```

Query: 181  tctctctgtgtaataagaagaattgggaaacgatcttcaaatatgcttaccagctgtgatt 240
           |||
Ref: 61801  tctctctgtgtaataagaagaattgggaaacgatcttcaaatatgcttaccagctgtgatt 61860

```

Query: 241 ccacatattacgtcaatcacacctgcacaggaggatgttttttagtagcaatttgtactgat 100
 Subject: 61861 ccacatattacgtcaatcacacctgcacaggaggatgttttttagtagcaatttgtacctgat 61920

perfect match!

Exhibit B

arrayit.com/weboligos.com
confidential

ARDC-119

5' NCA ACT GGG ACC ATT G 3'

N = Cy5

ARDC-120

5' NTT CTC C(T/A)C AGG AGT C 3'

N = C6 Amino modifier

ARDC-121

5' NAG GGC CTC ACC ACC A 3'

N = C6 Amino modifier

ARDC-122

5' NAA CAC CAA AGA TGA T 3'

N = C6 Amino modifier

ARDC-123

5' NCC TTA CCT GGC AGT G 3'

N = C6 Amino modifier

ARDC-124

5' NCA ATG GTT CCA GTT G 3'

N = C6 Amino modifier

Exhibit B

arrayit.com/weboligos.com
confidential

ARDC-109

5' NGG TAG TAA TGA GCG TGC AGC 3'

N = C6 Amino modifier

ARDC-110

5' NGA CTC CTG (A/T)GG AGA A 3'

N = Cy3

ARDC-111

5' NGA CTC CTA (A/T)GG AGA A 3'

N = Cy5

ARDC-112

5' NTG GTG GTG AGG CCC T 3'

N = Cy5

ARDC-113

5' NTG GTG GTA AGG CCC T 3'

N = Cy3

ARDC-114

5' NAT CAT CTT TGG TGT T 3'

N = Cy3

ARDC-115

5' NTA TCA TCG GTG TTT C 3'

N = Cy5

ARDC-116

5' NCA CTG CCA GGT AAG G 3'

N = Cy5

ARDC-117

5' NCA CTG CCG GGT AAG G 3'

N = Cy3

ARDC-118

5' NCA ACT GGA ACC ATT G 3'

N = Cy3

ARDC-100

5' NAA ACA GAC ACC ATG GTG CAC 3'

N = C6 Amino modifier

ARDC-101

5' NCC CAC AGG GCA GTA ACG GCA 3'

N = C6 Amino modifier

ARDC-102

5' NGC AAG GTG AAC GTG GAT GAA 3'

N = C6 Amino modifier

ARDC-103

5' NGT AAC CTT GAT ACC AAC CTG 3'

N = C6 Amino modifier

ARDC-104

5' NCT GGC ACC ATT AAA GAA AAT 3'

N = C6 Amino modifier

ARDC-105

5' NTT CTG TAT CTA TAT TCA TCA 3'

N = C6 Amino modifier

ARDC-106

5' NTG GGC TGT TCT AAC CCC CAC 3'

N = C6 Amino modifier

ARDC-107

5' NAA CCC ACT GGA GCC CCT GAC 3'

N = C6 Amino modifier

ARDC-108


5' NCC ACA GGA TCA GAG GCT GGG 3'

N = C6 Amino modifier



Nucleotide

Homo sapiens galactose-1-phosphate uridylyl transferase (GALT) gene, exon 10, with an N314D mutation prevalent in Duarte galactosemia (M96264 bases 2981-3250)



Go to:

1

Search for:


Comments and suggestions to: info@ncbi.nlm.nih.gov

Duarte allele: WT (A, Asn) N → D (mutant)
mutant (G, Asp) N314D



Nucleotide

Human galactose-1-phosphate uridylyl transferase (GALT) gene, exon 6, with a Q168R mutation prevalent in G/G Caucasian population causing reduced GALT activity (M96264 bases 1681-1670)



This is the understatement!

18 28 38 48 58 68 78 88 98 108 118 128 138 148 158 168 178 188 198 208 218 228 238 248 258 268 278 288 298 308 318 328 338 348 358 368 378 388 398 408 418 428 438 448 458 468 478 488 498 508 518 528 538 548 558 568 578 588 598 608 618 628 638 648 658 668 678 688 698 708 718 728 738 748 758 768 778 788 798 808 818 828 838 848 858 868 878 888 898 908 918 928 938 948 958 968 978 988 998

1 ACCGACGACG TCGTTCGCTG TCTTTTGGCT AGACAGGCTC CCATTCGCTA TCTATAAGT
GALIT

100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800 3900 4000 4100 4200 4300 4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400 5500 5600 5700 5800 5900 6000 6100 6200 6300 6400 6500 6600 6700 6800 6900 7000 7100 7200 7300 7400 7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 8500 8600 8700 8800 8900 9000 9100 9200 9300 9400 9500 9600 9700 9800 9900

61 CTTTCAATAC ATATGCTGCA TATGTCGCTG TTCTATCCGC CACCGACGAC CCCTCGTAG
GALIT

100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800 3900 4000 4100 4200 4300 4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400 5500 5600 5700 5800 5900 6000 6100 6200 6300 6400 6500 6600 6700 6800 6900 7000 7100 7200 7300 7400 7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 8500 8600 8700 8800 8900 9000 9100 9200 9300 9400 9500 9600 9700 9800 9900

121 GATATGATAC CCTCGACTCG CTTTCTTGCC TCGTCTGAC CCGACACTCT CCGACTGGCA
GALIT

100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800 3900 4000 4100 4200 4300 4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400 5500 5600 5700 5800 5900 6000 6100 6200 6300 6400 6500 6600 6700 6800 6900 7000 7100 7200 7300 7400 7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 8500 8600 8700 8800 8900 9000 9100 9200 9300 9400 9500 9600 9700 9800 9900

181 AACGAC
GALIT

100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800 3900 4000 4100 4200 4300 4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400 5500 5600 5700 5800 5900 6000 6100 6200 6300 6400 6500 6600 6700 6800 6900 7000 7100 7200 7300 7400 7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 8500 8600 8700 8800 8900 9000 9100 9200 9300 9400 9500 9600 9700 9800 9900

$$\begin{aligned} CAG &= \text{Gla}(Q) \\ CGG &= \text{Arg}(R) \end{aligned}$$

Q188R


Go to: Search for:

Comments and suggestions to: info@uchicago.edu

WT (a, Gln)
Mutant (g, Arg)

$$a \rightarrow g$$

Human cystic fibrosis transmembrane conductance regulator (CFTR) gene, exon 10 [331..831]



ΔFSI
 ΔTTT = ~~ΔS~~
 TTT = Phe(F)

ΔP508 = 3 nt. deletion of WT sequence

331..831

331

Comments and suggestions to: info@ncbi.nlm.nih.gov

Nucleotide

763

G 172A = C allele
A 173T = S allele
G 232A = F allele

1530 1548 1550 1568 1578 1588
 1521 AGGGCTGGCC ATTAAGATCA GGCACAGCC ATCTATTGCT TACHTTTCCT TCTGACACAC
 1590 1608 1618 1620 1630 1640
 1581 CTGTCTTTAC TAGGACATCC ATTCACACAC CATGCTGC CTCTACTCTC ACGGACATCC
 ARDC700 M V H L T P E E K S

GAG (Glu) \rightarrow AAG (Lys)
GAG (Glu) \rightarrow GTG (Val)
GAG (Glu) \rightarrow AAG (Lys)

Ex 21

ARDC-101

1641 1650 1668 1678 1686 1695 1706
 TGGCTTACT GGGCTGTGGG CCGAGTGTGA CCGATGTGA GTTGTCTGTG AGGGCTTGG
 A U Y R L U C K V H U D E V G G E A L C
 C-101 ARDC-102
 1701 1710 1728 1738 1746 1758 1766
 CCGTGTGTA TGGAGTTTAC AAGACAGCTT TAAAGAGACC AATTCAGACT GGGCATCTGC
 R ARDC-103

	1770	1780	1790	1800	1810	1820
1761	ACACACACAA	GACTCTTCCG	TTTCTGATAG	GCACCTACTC	TCTCTGCCAT	TTCTCTATT

	1830	1840	1850
1821	TYDOACDCT	TACCYCTC	BTGCTTACC CT
		L L	V V Y P

4(1...1201)

[1872...2832]▶

Use 6/3/98 formula
from Schema with.

$$T_c = -682 \times (2^{-1}) + 97 \quad \boxed{921}$$

$$T_w = T_c - 10^\circ\text{C}.$$

$$T_m = 420^{\circ}\text{C.}$$

15 min - $T_{\text{air}} = 35^{\circ}\text{C}$.

1) - $T_m = 25^\circ\text{C}$.

9- max - $T_m = 11^\circ\text{C}$

10-mer $T_m = 19^\circ\text{C}$.

Exhibit B

Neonatal Screening

Obtain 108 samples from Neo Gen

6 rows of 12 PCR tubes

Correspond to CF, B-globin and other loci and to Neo Gen samples A, B, C, D, E and F

50 ul PCR with 15 ul missing for agarose gels (gel bands look good)

Products look OK

All stored at -80C since arrival on

Remove from -80C, 72 samples and thaw

These correspond to 6 human loci, with quads of each locus and each genotype (wt, hetero and homo)

-Such that a given locus has 12 tubes

A. deltaF508WT, Hetero, Homo

B. B-globin 172/173 S/S, A/S, S/C

C. B-globin 172/173 C/C, A/C, A/A

D. B-globin 232 E/E, A/E, A/A

E. GALT 314 WT, Hetero, Homo

F. GALT 188 WT, Hetero, Homo

Add 160 ml of binding buffer

Mix 10X

Add to 384-well filter plate

-Add so that each set of four occupies a quad of wells

-ie. The first set of four is in A1, A2, B1, B2 and so forth

-Leave the 10th set of wells (A9, A10, B9, B10) empty so that samples will fall on even rows when printing 30 x30 in triplicate. ie. Last set of three spots will be empty for the first row.

Add 3 times to filter entire 200 ul vol

Spin briefly between loadings, then 5 min to dry filter

Add 50 ul H₂O, wait 2 min and elute by cent for 5 min

Allow 384-well plate to dry o/n under hood fan to dryness

After o/n drying under hood, the samples still contained ~20ul liquid

Dry in speedvac for 1.5 hrs at medium heat.

Add 5 ul H₂O to each well and mix well

Add 5 ul of 2X MSS-1 to each well and mix

To new 384-well plate, transfer 3 ul of each sample.

Also, add 3 ul to 5 additional quads of wells for each of 5 control 15-mer oligos

-Oligos are A5, B5, C5, D5, E5 (ARDC120-124) from weboligos 3/21/00 plate stored at -20C

-Oligos are amino-mods at 100 uM concentration, diluted 1:1 with 2X MSS-1 for a final conc of 50 uM.

Spin plate 5 min at 500 x g to move samples to bottom of plate

Array onto 30 SuperAldehydes using triplicate spotting at 140 uM spacing and 30 x 30 config

-Note that final arrays should contain 4 identical subgrids with 2 complete rows and the third containing 12 spots. The final 3 spots in row 1 should be 1X MSS-1

Printing looks good!

Store arrays in a substrate box for processing.

After o/n drying, label 2 arrays barcoded # 105034 and 105035

Demarcate array with diamond pencil on underside

Process as per published protocols

Soak 2X in 0.2% SDS

Soak 2X in dH₂O

Treat for 2 min at 95C in dH₂O

Spin dry 1 min

Exhibit B

Treat for 5 min in sodium borohydride (1.0 g in 400 ml dH₂O)
Rinse 3X in 0.2% SDS
Rinse 1X in dH₂O
Treat 2 sec at 95C in dH₂O
Spin dry 1 min

Hybridization:

Set array in hyb cassette
Add 10 ul of dH₂O
Prepare 2 cover slips 22 mm x 22 mm
Lay cover slip on top of array
Add 10 ul of 2-color fluorescent probes
-Probe are mixtures of 10 fluorescent oligos (5 Cy3 and 5 Cy5)
-Oligos are from weboligos 3/21/00 plate
-Cy3 are A1, B1, C1, D1 and E1
-Cy5 are A3, B3, C3, D3 and E3
-All 10 are in a 10 uM mixture stored at -20C
Probe 1: 10 oligos at 1 uM each final conc in 1X UniHyb
Probe 2: 10 oligos at 1 uM each final conc in 5X SSC + 0.2% SDS
Add probe 1 to array 105034 and probe 2 to array 105035
Hyb at 42C for 1.5 hrs
Wash 2X in 2X SSC + 0.2% SDS and 1X in 2X SSC for 5 min each
Spin dry 1 min
Scan at 100% PMT and 100% laser

Results:

Signals are rather weak but background is very low
Looks like the experiment is working!
See scans ms000420a-d
a-Cy3 with array 105034
b-Cy5 with array 105034
c-Cy3 with array 105035
d-Cy5 with array 105035

Second chip (SSC and SDS) slightly brighter signal. Quant data

Processing:

Process chips and compare direct labeling vs. NEN TSA on neonatal chips
Obtain 4 chips from rt drawer. Chips were made on SuperAldehyde on 4/19/00
Bar code as 105227-105230
Mark array with diamond pencil
Wash 2 x 2 min in 0.2% SDS and 2 x 2 min in dH₂O.
Denature 2 min at 95-100C in dH₂O.
Reduce in NaBH₄ for 5 min at rt [320 ml dH₂O + 1.2 g NaBH₄ + 120 ml 100% ethanol]
Wash 2 x 2 min in 0.2% SDS, 2 x 2 min in dH₂O. Spin dry.
Use for Hyb.

Hybs:

Exhibit B

Probes-

1. The Cy3/Cy5 mixture prepared on 4/20/00 and stored frozen at -20C. Mixture of 5 Cy3 oligos and 5 Cy5 oligos end-labeled corresponding to 1A-E and 3A-F from 3/24/00 weboligos source. All at 10 uM each. Make hyb mixture by mixing:

- 3 ul of 10 uM oligo mix
- 7.5 ul of 20X SSC
- 6 ul of 1% SDS
- 13.5 ul of dH2O
- 30 ul total volume.

Heat for 1 min at 65C

Spin for 1 min

Hyb to 105227 and 105228 under 22 mm x 22 mm cover slip, using 10 ul hyb solution per chip.

2. The biotin/DNA mixture prepared fresh on 6/7/00 and stored frozen at -20C after use. Mixture of 5 biotin oligos and 5 DNP oligos end-labeled corresponding to 1A-E and 7A-B from 5/24/00 weboligos source. All at 10 uM each. Make hyb mixture by mixing:

- 3 ul of 10 uM oligo mix
- 7.5 ul of 20X SSC
- 6 ul of 1% SDS
- 13.5 ul of dH2O
- 30 ul total volume.

Heat for 1 min at 65C

Spin for 1 min

Hyb to 105229 and 105230 under 22 mm x 22 mm cover slip, using 10 ul hyb solution per chip and 10 ul dH2O for humidification.

Hyb 4.5 hrs at 42C

Wash 2 x 5 min in 2X SSC + 0.2% SDS and 1 x 5 min in 2X SSC

Spin dry.

Scan chips 105227 and 105228 at 100% PMT and 100% laser with ScanArray 3000.

Exhibit B

		Cy3 raw	Cy3 Ave.	Cy3 Ave-Backgr.	Cy5 raw	Cy5 Ave.
Spot 28	1X MSS-1	2779			949	
Spot 29	"	3063	2964		1106	1123
Spot 30	"	3021			1313	
Spot 31	B-globin 232E/E	4986			1396	
Spot 32	B-globin 232E/E	5246	5358	2404	1395	1606
Spot 33	B-globin 232E/E	5841			2028	
Spot 34	B-globin 232A/E	3918			1831	
Spot 35	B-globin 232A/E	3706	3831	877	1429	1566
Spot 36	B-globin 232A/E	3868			1439	
Spot 37	B-globin 232A/A	3483			2871	
Spot 38	B-globin 232A/A	3126	3319	365	3133	2715
Spot 39	B-globin 232A/A	3347			2141	
		46384			21031	

Quantitation of two color genotyping on Neonatal chips printed on 4/19/00
Mixture of 10 fluorescent oligos to 5 loci in Cy3 and Cy5
Hyb buffer was 5X SSC + 0.2% SDS for 1.5 hrs at 42C
Probe solution was 1 uM each oligo
Washes were RT in 2X SSC + 0.2% SDS twice and once in 2X SSC
Scans were on GSIL 3000 at 100% laser and 100% PMT

Exhibit B




Exhibit B




Exhibit B



Exhibit B




Exhibit B




Exhibit B




Exhibit B




Exhibit B

